Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.50 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CCR3 | P51677 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26213682 | 0.88 | CARM1 (0.46) | PRMT6CARM1MEN1KMT2A | |
| SCHEMBL26213173 | 0.81 | SMN1; SMN2 (0.47) | PRMT6CARM1MAPTMEN1GAA | |
| SCHEMBL26213676 | 0.81 | DRD2 (0.33) | ALDH1A1GAAKMT2ASMN1; SMN2 | |
| SCHEMBL26213056 | 0.81 | KDM1A (0.53) | ALDH1A1 | |
| SCHEMBL26213678 | 0.78 | JAK2 (0.33) | — | |
| SCHEMBL26213112 | 0.78 | CARM1 (0.43) | PRMT6CARM1MAPTSLC6A2SLC6A3 | |
| SCHEMBL30270456 | 0.78 | CARM1 (0.43) | PRMT6CARM1MAPTSLC6A2SLC6A3 | |
| SCHEMBL26213077 | 0.77 | KDM1A (0.47) | MAPTSLC6A2SLC6A4ALDH1A1MEN1 | |
| SCHEMBL30270433 | 0.77 | PRMT6 (0.43) | PRMT6CARM1SLC6A2SLC6A4PRMT8 | |
| SCHEMBL26213120 | 0.77 | PRMT6 (0.43) | PRMT6CARM1SLC6A2SLC6A4PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843271-B | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2024-08-13 | — | — | CN | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| CN-115843271-A | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2023-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | CSNK2A1, IDO1, CSNK2A3 | PRMT6 1779/4885CARM1 2207/4885MAPT 2556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.